Search results
Results From The WOW.Com Content Network
FL is the most prevalent form of indolent lymphoma, accounting for 70% of indolent cases and 20–30% of all non-Hodgkin lymphoma cases, with a yearly incidence of 1.6 to 3.1 per 100,000. [13] [15] It is most frequently diagnosed among people in their 50s and 60s, and is more common among white populations than black or Asian populations. [14]
Of the many forms of lymphoma, some are categorized as indolent (e.g. small lymphocytic lymphoma), compatible with a long life even without treatment, whereas other forms are aggressive (e.g. Burkitt's lymphoma), causing rapid deterioration and death. However, most of the aggressive lymphomas respond well to treatment and are curable.
The disorder resembled certain aggressive GI tract lymphomas and was variably termed indolent lymphoma or indolent T cell lymphoproliferative disorder of the gastrointestinal tract. [4] However, the disease differed from the aggressive lymphomas which it mimicked in having a prolonged and usually non-progressive course.
Primary cutaneous diffuse large B-cell lymphoma, leg type is an aggressive B-cell lymphoma that is often resistant to therapy and carries a poor prognosis, [5] i.e., they have a 5-year disease-specific survival rate of 43% or 70% depending on whether their cancer cells have or do not have, respectively, inactivating mutations in both of their ...
Waldenström macroglobulinemia is an "indolent lymphoma" (i.e., one that tends to grow and spread slowly) and a type of lymphoproliferative disease which shares clinical characteristics with the indolent non-Hodgkin lymphomas. [4]
Plasmablastic lymphoma lesions are most commonly rapidly growing, soft tissue masses [5] that may be ulcerating, bleeding, and/or painful. [6] In a recent (2020) review of published cases, individuals presenting with PBD were typically middle-aged or elderly (range 1–88 years; median age 58 tears) males (~73% of cases). [7]
B-cell lymphoma-2 inhibitor, venetoclax, plus a CD20 antibody obinutuzumab, OR; BTKi (i.e. ibrutinib) plus BCL-2 inhibitor (i.e. venetoclax) [15] [16] [17] CLL is the most common type of leukemia in the Western world. It most commonly affects individuals over the age of 65, due to the accumulation of genetic mutations that occur over time.
Indolent condition is a condition that continues for a prolonged period. [1] Examples include: Indolent chronic lymphocytic leukemia or indolent CLL, which is a slow-progressing blood and bone marrow cancer, [2] Indolent lymphoma or low-grade lymphoma, a type of slow-growing non-Hodgkin lymphoma or slow-growing NHL. [3]